keyword
MENU ▼
Read by QxMD icon Read
search

Triple negative breast cancer

keyword
https://www.readbyqxmd.com/read/29928478/an-nf%C3%AE%C2%BAb-dependent-mechanism-of-tumor-cell-plasticity-and-lateral-transmission-of-aggressive-features
#1
Nancy Adriana Espinoza-Sánchez, Jennifer Enciso, Rosana Pelayo, Ezequiel M Fuentes-Pananá
Breast cancer is a complex disease exhibiting extensive inter- and intra-tumor heterogeneity. Inflammation is a well-known driver of cancer progression, often attributed to immune cells infiltrating the tumor stroma. However, tumor cells themselves are capable to secrete a variety of inflammatory molecules, of which we understand very little about their role in intra-clonal communication. We recently reported the capacity of triple negative cell lines to induce a cancer stem cell (CSC)-like phenotype and invasion properties into luminal cells, a mechanism mediated by pro-inflammatory cytokines that up-regulated the CXCL12/CXCR4/CXCR7 chemokine signaling axis...
June 1, 2018: Oncotarget
https://www.readbyqxmd.com/read/29928427/overexpression-of-cxxc5-is-a-strong-poor-prognostic-factor-in-er-breast-cancer
#2
Lei Fang, Yu Wang, Yang Gao, Xuejun Chen
CXXC5 is a newly identified CXXC-type zinc finger family protein, which is encoded by the CXXC5 gene localised to the 5q31.3 chromosomal region. Previous studies revealed that CXXC5 is associated with various malignant tumours. The aim of the present study was to investigate the prognosis prediction of CXXC5 in different breast cancer subtypes via the Gene Expression Omnibus database and bc-GenExMiner. CXXC5 overexpression was observed as associated with a poor prognosis for oestrogen receptor positive (ER+) breast cancer...
July 2018: Oncology Letters
https://www.readbyqxmd.com/read/29928384/-tp53-mutations-and-snps-as-prognostic-and-predictive-factors-in-patients-with-breast-cancer
#3
REVIEW
Joanna Huszno, Ewa Grzybowska
Tumor protein 53 ( TP53 ) is a tumor suppressor gene that encodes tumor protein p53. Tumor protein p53 regulates the expression of target genes in response to cellular stress. Additionally, p53 participates in the regulation of cell cycle checkpoints, DNA repair and apoptosis. Mutations in the TP53 gene are associated with numerous types of human cancer, including breast cancer, sarcomas, brain tumors and adrenal cortical carcinomas. In breast cancer, TP53 mutations are a negative prognostic factor. Tumors with TP53 mutations are more likely to be aggressive (triple-negative or human epidermal growth factor receptor 2-positive breast cancer), and resistant to chemotherapy and radiotherapy...
July 2018: Oncology Letters
https://www.readbyqxmd.com/read/29928062/novel-antibody-reagents-for-characterization-of-drug-and-tumor-microenvironment-induced-changes-in-epithelial-mesenchymal-transition-and-cancer-stem-cells
#4
Tony Navas, Thomas D Pfister, Simona Colantonio, Amina Aziz, Lynda Dieckman, Richard G Saul, Jan Kaczmarczyk, Suzanne Borgel, Sergio Y Alcoser, Melinda G Hollingshead, Young H Lee, Donald P Bottaro, Tara Hiltke, Gordon Whiteley, Naoko Takebe, Robert J Kinders, Ralph E Parchment, Joseph E Tomaszewski, James H Doroshow
The presence of cancer stem cells (CSCs) and the induction of epithelial-to-mesenchymal transition (EMT) in tumors are associated with tumor aggressiveness, metastasis, drug resistance, and poor prognosis, necessitating the development of reagents for unambiguous detection of CSC- and EMT-associated proteins in tumor specimens. To this end, we generated novel antibodies to EMT- and CSC-associated proteins, including Goosecoid, Sox9, Slug, Snail, and CD133. Importantly, unlike several widely used antibodies to CD133, the anti-CD133 antibodies we generated recognize epitopes distal to known glycosylation sites, enabling analyses that are not confounded by differences in CD133 glycosylation...
2018: PloS One
https://www.readbyqxmd.com/read/29927112/generating-conformation-specific-polyclonal-and-monoclonal-anti-protein-kinase-c-antibodies-and-anti-active-state-specific-pkc-antibodies
#5
Darlene A Pena, Denise M V Pacheco, Paulo S L Oliveira, Maria J M Alves, Deborah Schechtman
The protein kinase C (PKC) family of serine/ threonine kinases has been shown to play active roles as either suppressors or promoters of carcinogenesis in different types of tumors. Using antibodies that preferentially recognize the active conformation of classical PKCs (cPKCs), we have previously shown that in breast cancer samples the expression levels of cPKCs were similar in estrogen receptor-positive (ER+ ) as compared to triple-negative tumors; however, the levels of active cPKCs were different. Determining the activation status of PKCs and other kinases in tumors may thus aid therapeutic decisions...
June 2018: Current Protocols in Chemical Biology
https://www.readbyqxmd.com/read/29926386/cxcl12-chemokine-and-cxcr4-receptor-association-with-susceptibility-and-prognostic-markers-in-triple-negative-breast-cancer
#6
Alda Losi Guembarovski, Roberta Losi Guembarovski, Bruna Karina Banin Hirata, Glauco Akelinghton Freire Vitiello, Karen Mayumi Suzuki, Mayara Tiemi Enokida, Maria Angelica Ehara Watanabe, Edna Maria Vissoci Reiche
CXCL12/CXCR4 signaling has been implicated in breast carcinogenesis, and genetic polymorphisms in these molecules have been associated with different types of cancer. The present study analyzed genetic polymorphisms in CXCL12 (rs1801157, G > A) and CXCR4 (rs2228014, C > T) and CXCR4 immunostaining in tumor tissues from patients with triple negative breast cancer (TNBC) aiming to evaluate their possible role in its' susceptibility and prognosis. Genetic polymorphisms were analyzed in 59 TNBC patients and 150 control women; age-adjusted logistic regression showed no association when variants were considered in isolation; however, a statistically significant interaction was noted for heterozygosis for both allelic variants increasing the odds for TNBC (CXCL12-GA by CXCR4-CT: OR 7...
June 20, 2018: Molecular Biology Reports
https://www.readbyqxmd.com/read/29925694/targeting-the-human-muc1-c-oncoprotein-with-an-antibody-drug-conjugate
#7
Govind Panchamoorthy, Caining Jin, Deepak Raina, Ajit Bharti, Masaaki Yamamoto, Dennis Adeebge, Qing Zhao, Roderick Bronson, Shirley Jiang, Linjing Li, Yozo Suzuki, Ashujit Tagde, P Peter Ghoroghchian, Kwok-Kin Wong, Surender Kharbanda, Donald Kufe
Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly overexpressed on the surface of diverse human carcinomas and is an attractive target for the development of mAb-based therapeutics. However, attempts at targeting the shed MUC1 N-terminal subunit have been unsuccessful. We report here the generation of mAb 3D1 against the nonshed oncogenic MUC1 C-terminal (MUC1-C) subunit. We show that mAb 3D1 binds with low nM affinity to the MUC1-C extracellular domain at the restricted α3 helix. mAb 3D1 reactivity is selective for MUC1-C-expressing human cancer cell lines and primary cancer cells...
June 21, 2018: JCI Insight
https://www.readbyqxmd.com/read/29925435/tumor-analysis-freeze-thawing-cycle-of-triple-negative-breast-cancer-cells-alters-tumor-cd24-cd44-profiles-and-the-percentage-of-tumor-infiltrating-immune-cells
#8
Matthieu Le Gallo, Thibault de la Motte Rouge, Amanda Poissonnier, Vincent Lavoué, Patrick Tas, Jean Leveque, Florence Godey, Patrick Legembre
OBJECTIVE: The use of novel methods to characterize living tumor cells relies on well-conceived biobanks. Herein, we raised the question of whether the composition of fresh and freeze/thawed dissociated tumor samples is comparable in terms of quantitative and qualitative profiling. RESULTS: Breast cancer is a heterogeneous disease, encompassing luminal A and B, basal/triple-negative breast cancer (TNBC), and ERBB2-like tumors. We examined living cells dissociated from TNBC and found that a classical freeze/thaw protocol leads to a marked reduction in the number of CD45- CD44Low CD24Low tumor cells...
June 20, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29924962/prognostic-value-of-aldehyde-dehydrogenase-1-aldh1-in-invasive-breast-carcinomas
#9
Hale Demir, Ozgecan Dulgar, Bugra Taygun Gulle, Hande Turna, Sennur Ilvan
Aldehyde dehydrogenase 1 (ALDH1) has been identified as a marker of cancer stem cells in breast cancer (BC). Recent studies showed that ALDH1 expression is correlated with poor prognostic parameters and worse clinical outcome in BC. We evaluated ALDH1 expression by immunohistochemistry in a series of 217 invasive BCs and investigated the correlation between ALDH1 expression and clinicopathological parameters, molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 [HER2] type, and triple-negative BC [TNBC]), and patient survival...
June 11, 2018: Bosnian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/29924958/overexpression-of-mir-361-5p-in-triple-negative-breast-cancer-tnbc-inhibits-migration-and-invasion-by-targeting-rqcd1-and-inhibiting-the-egfr-pi3k-akt-pathway
#10
Jianjun Han, Jingjing Yu, Yuna Dai, Jumei Li, Meiyan Guo, Jingzhen Song, Xuefeng Zhou
Triple-negative breast cancer (TNBC) is the leading cause of cancer-related death in women. Previous studies indicated that miR-361-5p was downregulated in breast cancer, however, the exact effect of miR-361-5p on TNBC requires further investigation. In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC...
June 20, 2018: Bosnian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/29923998/clinical-study-on-postoperative-triple-negative-breast-cancer-with-chinese-medicine-study-protocol-for-an-observational-cohort-trial
#11
Jiajing Chen, Yuenong Qin, Chenping Sun, Wei Hao, Shuai Zhang, Yi Wang, Juan Chen, Lixin Chen, Yiying Ruan, Sheng Liu
BACKGROUND: Breast cancer (BC) poses a tremendous threat to the health of women worldwide, especially triple-negative breast cancers (TNBCs). Currently, the curative effect of traditional Chinese medicine (TCM) has been recognized in more and more people worldwide; however, the specific effect has not been systematically evaluated. The purpose of this cohort study is to evaluate the clinical effects of TCM syndrome differentiation on recurrence and metastasis rate, survival rate, and the quality of life in patients with TNBC...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29923634/radioimmunoimaging-and-targeting-treatment-in-an-immunocompetent-murine-model-of-triple-negative-breast-cancer-using-radiolabeled-anti-pd-l1-monoclonal-antibody
#12
Xiaoxi Pang, Meng Liu, Rongfu Wang, Xuhe Liao, Ping Yan, Chunli Zhang
The overall aim of this study was to evaluate whether iodine-131 radiolabeled monoclonal antibody (mAb) targeting PD-L1 can be used for imaging of PD-L1 expression noninvasively in vivo, and playing synergistic effect combined with immunotherapy. Anti-PD-L1 mAb was radiolabeled with iodine-131 (131 I-PD-L1 mAb), and was characterized in vitro. Biodistribution and imaging in vivo were performed periodically. Therapy study was conducted in triple-negative breast cancer bearing BALB/c mice. As results, the labeling efficiencies of 131 I-PD-L1 mAb reached 80 % ± 3 %, with radiochemical purity was 97 % ± 1 %...
June 20, 2018: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29923083/micrornas-in-regulation-of-triple-negative-breast-cancer-progression
#13
REVIEW
Dominika Piasecka, Marcin Braun, Radzislaw Kordek, Rafal Sadej, Hanna Romanska
PURPOSE: Dysregulation of miRNA profile has been associated with a broad spectrum of cellular processes underlying progression of various human malignancies. Increasing evidence suggests that specific microRNA clusters might be of clinical utility, especially in triple-negative breast carcinoma (TNBC), devoid of both predictive markers and potential therapeutic targets. Here we provide a comprehensive review of the existing data on microRNAs in TNBC, their molecular targets, a putative role in invasive progression with a particular emphasis on the epithelial-to-mesenchymal transition (EMT) and acquisition of stem-cell properties (CSC), regarded both as prerequisites for metastasis, and significance for therapy...
June 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29921827/differential-expression-and-pathway-analysis-in-drug-resistant-triple-negative-breast-cancer-cell-lines-using-rnaseq-analysis
#14
Safa Shaheen, Febin Fawaz, Shaheen Shah, Dietrich Büsselberg
Triple-negative breast cancer (TNBC) is among the most notorious types of breast cancer, the treatment of which does not give consistent results due to the absence of the three receptors (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) as well as high amount of molecular variability. Drug resistance also contributes to treatment unresponsiveness. We studied differentially expressed genes, their biological roles, as well as pathways from RNA-Seq datasets of two different TNBC drug-resistant cell lines of Basal B subtype SUM159 and MDA-MB-231 treated with drugs JQ1 and Dexamethasone, respectively, to elucidate the mechanism of drug resistance...
June 19, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29921732/chemotherapy-sensitizes-therapy-resistant-cells-to-mild-hyperthermia-by-suppressing-heat-shock-protein-27-expression-in-triple-negative-breast-cancer
#15
Haifa Shen, Chaofeng Mu, Xiaoyan Wu, Xinyu Zhou, Joy Wolfram, Jianliang Shen, Dechen Zhang, Junhua Mai, Xiaojun Xia, Ashley M Holder, Mauro Ferrari, Xuewu Liu
PURPOSE: Triple-negative breast cancer (TNBC) is a clinically aggressive disease with poor prognosis. Conventional chemotherapeutics are generally able to shrink the tumor mass, but often fail to completely eradicate cancer stem-like cells (CSCs) that are responsible for high risk of relapse and frequent metastases. In this study, we examined thermal sensibility of CSCs, developed an approach that enabled concurrent elimination of both the bulk of cancer cells and CSCs, and investigated the underlying mechanism...
June 19, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29921380/different-molecular-subtypes-of-breast-invasive-ductal-carcinoma
#16
L J Zheng, D Yang, L J Sun, S S Li, J Y Wang, S C Ye
This study aims to analyze the clinical characteristics of breast invasive ductal carcinoma (BIDC) in patients with different molecular subtypes and identify possible correlation to prognosis. miR- 10b expression level was detected using real-time quantitative polymerase chain reaction (RT-PCR). Tissue sections were collected and stained using the immunohistochemical method. The samples were grouped into human epidermal growth factor receptor 2, (HER2) overexpression, Triple negative, Luminal A and Luminal B groups...
May 2018: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/29921315/expression-of-id4-protein-in-breast-cancer-cells-induces-reprogramming-of-tumour-associated-macrophages
#17
Sara Donzelli, Elisa Milano, Magdalena Pruszko, Andrea Sacconi, Silvia Masciarelli, Ilaria Iosue, Elisa Melucci, Enzo Gallo, Irene Terrenato, Marcella Mottolese, Maciej Zylicz, Alicja Zylicz, Francesco Fazi, Giovanni Blandino, Giulia Fontemaggi
BACKGROUND: As crucial regulators of the immune response against pathogens, macrophages have been extensively shown also to be important players in several diseases, including cancer. Specifically, breast cancer macrophages tightly control the angiogenic switch and progression to malignancy. ID4, a member of the ID (inhibitors of differentiation) family of proteins, is associated with a stem-like phenotype and poor prognosis in basal-like breast cancer. Moreover, ID4 favours angiogenesis by enhancing the expression of pro-angiogenic cytokines interleukin-8, CXCL1 and vascular endothelial growth factor...
June 19, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29920512/systems-modelling-of-the-egfr-pyk2-c-met-interaction-network-predicts-and-prioritizes-synergistic-drug-combinations-for-triple-negative-breast-cancer
#18
Sung-Young Shin, Anna-Katharina Müller, Nandini Verma, Sima Lev, Lan K Nguyen
Prediction of drug combinations that effectively target cancer cells is a critical challenge for cancer therapy, in particular for triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype with no effective targeted treatment. As signalling pathway networks critically control cancer cell behaviour, analysis of signalling network activity and crosstalk can help predict potent drug combinations and rational stratification of patients, thus bringing therapeutic and prognostic values. We have previously showed that the non-receptor tyrosine kinase PYK2 is a downstream effector of EGFR and c-Met and demonstrated their crosstalk signalling in basal-like TNBC...
June 2018: PLoS Computational Biology
https://www.readbyqxmd.com/read/29916188/new-horizons-in-breast-cancer-the-promise-of-immunotherapy
#19
REVIEW
L de la Cruz-Merino, N Palazón-Carrión, F Henao-Carrasco, E Nogales-Fernández, M Álamo-de la Gala, A Vallejo-Benítez, M Chiesa, V Sánchez-Margalet
Immunology and immunotherapy of cancer is an expanding field in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in which host immune responses have been also recently demonstrated of critical relevance...
June 18, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29915946/impact-of-change-in-body-mass-index-during-neoadjuvant-chemotherapy-and-survival-among-breast-cancer-subtypes
#20
Takahiro Kogawa, Takeo Fujii, Tamer M Fouad, Diane D Liu, Kenichi Harano, Hiroko Masuda, Toshiaki Iwase, Chad Barnett, Young Sam Park, Bora Lim, Debu Tripathy, Jennifer K Litton, Naoto T Ueno
PURPOSE: We hypothesized that an increase in BMI category during neoadjuvant chemotherapy (NAC) would be associated with pathological complete response (pCR) rate and worse survival outcomes in primary breast cancer patients. METHODS: We reviewed the records of 4029 patients with stage I-III breast cancer who had undergone NAC and definitive surgery at our institution between May 1, 1990 and April 30, 2013. BMI values at baseline and after NAC were recorded, and the corresponding BMI category was assessed with the WHO classification...
June 18, 2018: Breast Cancer Research and Treatment
keyword
keyword
3592
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"